Quotables
"Fooling around with alternating current is just a waste of time. Nobody will use it, ever."
Thomas Edison ; 1889
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110664 | Binding partners for the thyrotropin receptor and uses thereof A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the sa... | 02/07/2012 |
| 8101727 | Compositions and methods of use for antibodies of c-Met Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a... | 01/24/2012 |
| 8101726 | Ligands binding the complex of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) that inhibit downstream uPAR interactions: identification and use in diagnosis or therapy Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the... | 01/24/2012 |
| 8097705 | Methods and compositions for treating allergic diseases Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling. ... | 01/17/2012 |
| 8080639 | Antibodies which bind specifically to activin receptor like kinase 3 A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-β-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence i... | 12/20/2011 |
| 8039598 | Met fab and SCFV fragments Antibody fragments (Fabs and scFvs) specific to the Met receptor are disclosed. Compositions and kits including these Fabs and scFvs, and drug and imaging conjugates of these Fabs and scFvs also are disclosed. The novel Fabs and scFvs can be internalized into the in... | 10/18/2011 |
| 8008451 | Antibodies to TNF (tumor necrosis factor) receptor family members Polypeptide produced from human stromal cell line, the process for the preparation of the polypeptide, DNA encoding the polypeptide, vector carrying the DNA, host cell transformed by the vector, antibody of the polypeptide, and pharmaceutical composition containing ... | 08/30/2011 |
| 7994292 | MU-1, member of the cytokine receptor family Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins, antibodies (and fragments thereof) that specifically bind to MU-1 proteins (and fragments thereof), and methods for their production are al... | 08/09/2011 |
| 7947811 | Antibodies that bind specifically to human RON protein The invention provides antibodies or fragments thereof, including human antibodies, specific for Macrophage-Stimulating Protein Receptor (MSP-R or RON), which inhibit RON activation. Also provided are methods to inhibit RON, particularly the use of RON antibodies to... | 05/24/2011 |
| 7935794 | MAdCAM antibodies The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease. ... | 05/03/2011 |
| 7915390 | Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibod... | 03/29/2011 |
| 7888483 | Antagonists of protease activated receptor-1 (PAR1) The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleo... | 02/15/2011 |
| 7888482 | Antibodies that bind PAR-2 The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-bindi... | 02/15/2011 |
| 7879985 | Antibodies against human NKG2D and uses thereof The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to... | 02/01/2011 |
| 7858757 | Monoclonal antibodies with specificity for fetal erythroid cells The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleat... | 12/28/2010 |
| 7851600 | Anti-CCR5 antibody The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprisi... | 12/14/2010 |
| 7825224 | Product and method for treatment of conditions associated with receptor-desensitization Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be phys... | 11/02/2010 |
| 7812136 | Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa. ... | 10/12/2010 |
| 7790863 | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compos... | 09/07/2010 |
| 7777009 | Compositions for detecting and treating diseases and conditions related to chemokine receptors Antibodies that bind CCX-CKR2 are described. ... | 08/17/2010 |
| 7759465 | Antibodies to toll-like receptor-2 It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectivel... | 07/20/2010 |
| 7723489 | Use of blocking anti-TSH-receptor-antibodies in the therapy of hyperthyreoses and monoclonal antibodies for a use of this type Use of blocking antibodies against the human TSH receptor (hTSH receptor) or their specifically binding fragments for the treatment of, or for preparation of drugs for the treatment of, hyperthyroidism which is attributable to stimulating autoantibodies against the ... | 05/25/2010 |
| 7718778 | Antibody reactive with human toll like receptor 3 Toll Like Receptor 3 (TLR3) modulators, such as antibodies, polynucleotides encoding TLR3 antibodies or fragments thereof, and methods of making and using the foregoing are disclosed. ... | 05/18/2010 |
| 7700742 | Antibodies to insulin-like growth factor I receptor The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeri... | 04/20/2010 |
| 7678891 | Antibodies that bind CCX-CKR2 Antibodies that bind to CCX-CKR2 and methods of their use are provided. ... | 03/16/2010 |
| 7674884 | Neutralizing antibodies and methods of use thereof This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using t... | 03/09/2010 |
| 7662928 | Anti-FcRn antibodies for treatment of auto/allo immune conditions Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reduc... | 02/16/2010 |
| 7642341 | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positi... | 01/05/2010 |
| 7622560 | Monoclonal antibody specific for CD43 epitope The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but no... | 11/24/2009 |
| 7592428 | Antibodies which bind specifically to activin receptor like kinases A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-β-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence i... | 09/22/2009 |
| 7569675 | High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage com... | 08/04/2009 |
| 7521542 | Humanized FcγRIIB-specific antibodies and methods of use thereof The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the... | 04/21/2009 |
| 7485703 | Antibody against G-protein coupled receptor showing selective affinity for ATP and uses therefor The present invention relates to isolated antibodies both polyclonal and monoclonal, that specifically bind to a G-protein coupled receptor showing selective affinity for ATP. The invention further comprises a pharmaceutical composition comprising antibodies that sp... | 02/03/2009 |
| 7470775 | Anti-CD30 stalk and anti-CD30 antibodies suitable for use in immunotoxins CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains... | 12/30/2008 |
| 7456263 | P53 binding T cell receptor molecules The invention provides T-cell receptor (TCR) molecules comprising a Vα chain and a Vβ chain that bind peptides derived from the p53 protein, preferably, the human p53 protein. The TCR molecules include both heterodimeric molecules and single chain molecules which ... | 11/25/2008 |
| 7438906 | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies. ... | 10/21/2008 |
| 7438907 | Human monoclonal antibodies against CD25 Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgeni... | 10/21/2008 |
| 7438905 | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositi... | 10/21/2008 |
| 7435803 | Anti-CD20 antibodies and fusion proteins thereof and methods of use The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignan... | 10/14/2008 |
| 7435796 | Antibodies which bind B7RP1 Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists ... | 10/14/2008 |
